LIVECAST Markets Briefs Calendar Search

Research

AI Market Assistant Instrument directory Macro Politics Prediction Markets News Archive

LIVECAST Markets

☀◐Theme

Menu

Home LIVECAST Markets Briefs Calendar Search AI Market Assistant Instrument directory Macro Politics Prediction Markets News Archive Account

Live News REGULATION FLASH L impact Sep 21, 2026, 11:00 AM UTC

PGEN - Precigen Receives FDA Platform Technology Designation for AdenoVerse Platform

SquawkNews Newsroom

Use this page

Share or save this market-moving headline as a permanent SquawkNews URL. The live feed continues at /news.

Open live news feed Browse news archive Browse news categories Search related coverage

Related tickers

PGEN

Related stories

Germany launches tender to secure gas availability for early 2027 German natural gas market operator Trading Hub Europe (THE) has launched several tenders to secure gas availability during the first quarter of 2027, amid concerns over low storage M impact | REGULATION | Sep 21, 2026, 11:34 AM UTC Cingulate gets FDA Complete Response Letter for CTx-1301 Cingulate said the FDA issued a Complete Response Letter for its CTx-1301 NDA on June 1, 2026, and the company is addressing CMC issues with plans to resubmit promptly. Management M impact | REGULATION | Sep 21, 2026, 11:28 AM UTC UK campaigners urge regulators to act on climate risk, fossil fuel underwriting Environmental campaigners have urged Britain's financial regulators to enforce consumer duty rules for insurers exiting high-risk markets and to raise capital requirements for unde M impact | REGULATION | Sep 21, 2026, 11:09 AM UTC EU proposes data centre efficiency disclosure rules The European Commission has proposed rules requiring data centres in Europe to disclose their energy and water efficiency. Operators of facilities with a capacity of 500 kW would n M impact | REGULATION | Sep 21, 2026, 11:09 AM UTC FDA grants priority review to Insmed's ARIKAYCE for MAC lung disease FDA accepted Insmed's supplemental New Drug Application (sNDA) for ARIKAYCE in MAC lung disease as part of combination therapy, granting Priority Review. The Prescription Drug User M impact | REGULATION | Sep 21, 2026, 11:08 AM UTC FDA grants priority review to Insmed ARIKAYCE sNDA FDA granted priority review to Insmed's supplemental new drug application (sNDA) for ARIKAYCE® (amikacin liposome inhalation suspension) to treat MAC lung disease. The Prescription M impact | REGULATION | Sep 21, 2026, 11:00 AM UTC

SQUAWK/NEWS

Live financial news for traders. Read the headline on screen or hear it through LiveCast while you stay on the trade.

LiveCast passes from $15 · Institutional API access.

Start LiveCast

Product

Open LiveCast
Plans & Pricing
Institutional API
How LiveCast Works
Live Markets
Session Briefs
RSS Feed
Calendar
Search
Instrument directory

Research

Macro
Politics
Prediction Markets
AI Market Assistant
News Archive

For Traders

Market Movers
US Stocks
Why News Moves Markets
News for Traders
How to Trade the News
What Is an Audio Squawk?
Policy Calendar

Company

About
Why SquawkNews
Newsroom
Editorial Standards
Corrections
Contact us

Legal

Privacy Policy
Terms of Use

© 2026 SquawkNews SquawkNews publishes market information and context. It does not provide investment advice or trade recommendations.